Scarica l'app Stockscreener
1.86
0.54%
0.01
Dopo l'orario di chiusura:
1.86
Precedente Chiudi:
$1.85
Aprire:
$1.85
Volume 24 ore:
2.49M
Relative Volume:
1.46
Capitalizzazione di mercato:
$391.14M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-3.5769
EPS:
-0.52
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
+8.77%
1M Prestazione:
+39.85%
6M Prestazione:
+35.77%
1 anno Prestazione:
+96.85%
Intervallo 1D:
$1.78
$1.86
Intervallo di 1 settimana:
$1.63
$1.86
Portata 52W:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN
Akebia Therapeutics to present at upcoming investor conferences - MSN
Akebia Therapeutics (AKBA) Set to Announce Earnings on Thursday - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard
Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World
Akebia stock climbs 8% on dialysis provider supply agreement - MSN
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St
Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia
Akebia Therapeutics secures dialysis drug contract - Investing.com
Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne
Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com
Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK
Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - StockTitan
A new trading data show Akebia Therapeutics Inc. (AKBA) is showing positive returns. - SETE News
Akebia Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
Akebia shares maintain Buy rating on CMS Vafseo payment decision By Investing.com - Investing.com Canada
Marshall Wace LLP Lowers Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia shares maintain Buy rating on CMS Vafseo payment decision - Investing.com India
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - Lelezard
Akebia Therapeutics Inc. [AKBA] Records 200-Day SMA of $1.3806 - Knox Daily
Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges - GuruFocus.com
Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
A stock that deserves closer examination: Akebia Therapeutics Inc. (AKBA) - US Post News
Ratio Revelations: Akebia Therapeutics Inc. (AKBA)’s Financial Metrics in the Spotlight - The Dwinnex
Akebia shares gain momentum as analyst highlights Vafseo's market potential in dialysis centers - Investing.com
Akebia Therapeutics (NASDAQ:AKBA) Given "Buy" Rating at HC Wainwright - MarketBeat
Examining the Potential Price Growth of Akebia Therapeutics Inc. (AKBA) - Knox Daily
Akebia, U.S. Renal Care sign dialysis treatment supply deal - Investing.com
Akebia, U.S. Renal Care sign dialysis treatment supply deal By Investing.com - Investing.com UK
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Marketscreener.com
Akebia Therapeutics Inc. (AKBA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
SVP, Chief Legal Officer Hadas Nicole R. sale 12,016 shares of Akebia Therapeutics Inc. [AKBA] - Knox Daily
Akebia Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2022 to Discuss Your RightsAKBA - Newsfile
Chartwell Partners Recruits CFO for Akebia Therapeutics - Hunt Scanlon Media
Alerce Investment Management L.P. Sells 7,457,213 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Ratios in Focus: Analyzing Akebia Therapeutics Inc. (AKBA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.88%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):